about
Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published EvidenceManagement of Musculoskeletal Manifestations in Inflammatory Bowel DiseasePhysicochemical and Biological Characterization of the Proposed Biosimilar Tocilizumab.Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.Novel systemic therapies for the treatment of psoriasis.Anti-TNF-α therapies for the treatment of Crohn's disease: the past, present and future.Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.Current challenges and emerging drug delivery strategies for the treatment of psoriasis.Biosimilar epoetin zeta: extrapolation of indications and real world utilization experience.Etanercept (SB4): A Review in Autoimmune Inflammatory Diseases.Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.Interchangeability of Biosimilars: A European Perspective.The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar.Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassaysEuropean Experience of Infliximab Biosimilars for the Treatment of Inflammatory Bowel Disease.Ineffectiveness of infliximab CT-P13 for the treatment of scleromyxedema: A case report.Profile of infliximab in the treatment of pediatric Crohn's disease.Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars.Preemptive Dose Optimization Using Therapeutic Drug Monitoring for Biologic Therapy of Crohn's Disease: Avoiding Failure While Lowering Costs?Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center.Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts.A bibliometric analysis of the global research on biosimilars.A descriptive analysis of real-world treatment patterns of innovator (Remicade) and biosimilar infliximab in an infliximab-naïve Turkish populationThe performance of Remicade®-optimized quantification assays in the assessment of Flixabi® levels
P2860
Q28078423-EBA65F63-48C7-4D02-9563-6124D5EA264AQ35773115-D04EF4B8-7A6A-46A0-937F-360BA701041CQ37703405-99706199-CF6A-482A-90E5-6F09ED09D362Q38586029-46B3AB63-0B90-449C-8539-A7757FAD94BAQ38591241-A2ED676F-A1CA-40B7-8625-2B2CEB77BEB6Q38628193-CA82DB23-C81D-41C5-9D0D-F2515422BFFEQ38652276-3E2DBC98-8CA0-4C1D-A8B1-A7AFF9F7A7BCQ38708927-88E7C350-604F-4BAA-8C9C-20D71DCF7200Q38831055-111998E1-A080-40FF-9221-431E6D463DF1Q38844794-75E480AB-8B09-4039-A5C7-2FD4E506D1A8Q38907998-092E02E0-1973-47B5-BC9B-34EE97A09D77Q38960108-F64A1F66-A22C-4A52-B79A-EB13788208E4Q38994573-B580E3BA-5DC4-4E5F-99D1-4BAE43986D36Q39000780-6C3011D4-BF3C-466F-BE36-1030F8DD9575Q39018436-DBB30CFC-6A91-48DC-AC12-8E6F7F45B97CQ41078498-D0AA6ED5-D50F-4BCC-8353-028788AAE50DQ41504139-30FDC6D3-25FE-4E73-8D8C-A533E3E82906Q48162070-F966B176-F47E-4381-A2C4-4B5D581B363BQ49165025-F33BE3D3-7254-4CB5-BAF3-E0803CBDE5F6Q50870659-D34BE1F2-F0E4-4F2B-A447-F2B37AC00EC3Q50924415-EB84061C-5999-4B84-98A7-0AB9B73C3F71Q53444169-A2463A1D-AD26-46C8-8043-BBFA2EB6B4A8Q55212098-F5CF2FB7-4A82-4076-B987-2B0D8C1D8CD4Q55239713-B51CB434-DFC8-407D-89D6-A97739E645E7Q57484897-EB1B2A2E-7E8C-41AD-A1F7-C0784A92CF6BQ58701964-94F8C2C0-FD0E-48A2-A206-D3FB14F04914
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
A review of CT-P13: an infliximab biosimilar.
@en
type
label
A review of CT-P13: an infliximab biosimilar.
@en
prefLabel
A review of CT-P13: an infliximab biosimilar.
@en
P2860
P1433
P1476
A review of CT-P13: an infliximab biosimilar.
@en
P2093
Kate McKeage
P2860
P2888
P304
P356
10.1007/S40259-014-0094-1
P577
2014-06-01T00:00:00Z